Alterity Therapeutics Ltd Share Price Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 6.77Cr 5.87Cr 5.54Cr 5.03Cr 9.43Cr 649.36Cr 9.49Cr 66Cr 26Cr 329.36Cr 25Cr 25Cr 1.05TCr | P/E 2027 * |
-3.15x | P/E 2028 * | -0.39x |
|---|---|---|---|---|---|
| Enterprise Value | 2.68Cr 2.32Cr 2.19Cr 1.99Cr 3.73Cr 256.98Cr 3.76Cr 26Cr 10Cr 130.34Cr 10Cr 9.84Cr 415.47Cr | EV / Sales 2027 * |
56.3x | EV / Sales 2028 * | 15.4x |
| Free-Float |
97% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 07/01/2021 |
| Director of Finance/CFO | - | 30/09/2024 | |
| Chief Tech/Sci/R&D Officer | - | 01/04/2019 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 29/07/2005 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 08/08/2011 |
David Stamler
BRD | Director/Board Member | 65 | 21/11/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 6.77Cr | |
| +0.15% | +0.64% | -1.36% | +26.89% | 4.59TCr | |
| -0.32% | +4.61% | +43.90% | +26.98% | 4.42TCr | |
| -4.36% | -5.66% | +338.30% | +516.88% | 4.2TCr | |
| +0.46% | -0.83% | +6.38% | +73.76% | 3.96TCr | |
| -0.17% | -3.22% | +10.29% | +38.69% | 3.11TCr | |
| -0.65% | +5.14% | +25.61% | +120.17% | 1.72TCr | |
| +3.30% | -5.03% | - | - | 1.63TCr | |
| +2.22% | +7.70% | +21.66% | +38.82% | 1.5TCr | |
| +0.86% | +9.05% | +0.47% | -33.54% | 1.34TCr | |
| Average | +0.35% | +1.18% | +55.66% | +101.08% | 2.94TCr | |
| Weighted average by Cap. | -0.34% | +0.31% | +70.17% | +122.60% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 5L 4L 4L 4L 7L 4.56Cr 7L 46.49L 17.96L 2.31Cr 17.86L 17.46L 7.37Cr | 19.78L 17.14L 16.2L 14.71L 27.57L 19Cr 27.74L 1.93Cr 74.75L 9.63Cr 74.32L 72.67L 31Cr |
| Net income | -2.75Cr -2.39Cr -2.26Cr -2.05Cr -3.84Cr -264.19Cr -3.86Cr -27Cr -10Cr -134Cr -10Cr -10Cr -427.12Cr | -3.08Cr -2.67Cr -2.53Cr -2.29Cr -4.3Cr -295.9Cr -4.32Cr -30Cr -12Cr -150.08Cr -12Cr -11Cr -478.38Cr |
| Net Debt | -4.09Cr -3.54Cr -3.35Cr -3.04Cr -5.7Cr -392.38Cr -5.73Cr -40Cr -15Cr -199.02Cr -15Cr -15Cr -634.37Cr | -3.72Cr -3.22Cr -3.04Cr -2.76Cr -5.18Cr -356.41Cr -5.21Cr -36Cr -14Cr -180.77Cr -14Cr -14Cr -576.21Cr |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
